73 related articles for article (PubMed ID: 22483089)
1. Design, synthesis and biological evaluation of thiazole- and indole-based derivatives for the treatment of type II diabetes.
Xu Q; Huang L; Liu J; Ma L; Chen T; Chen J; Peng F; Cao D; Yang Z; Qiu N; Qiu J; Wang G; Liang X; Peng A; Xiang M; Wei Y; Chen L
Eur J Med Chem; 2012 Jun; 52():70-81. PubMed ID: 22483089
[TBL] [Abstract][Full Text] [Related]
2. Novel euglycemic and hypolipidemic agents. 1.
Lohray BB; Bhushan V; Rao BP; Madhavan GR; Murali N; Rao KN; Reddy AK; Rajesh BM; Reddy PG; Chakrabarti R; Vikramadithyan RK; Rajagopalan R; Mamidi RN; Jajoo HK; Subramaniam S
J Med Chem; 1998 May; 41(10):1619-30. PubMed ID: 9572887
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
Onda K; Shiraki R; Ogiyama T; Yokoyama K; Momose K; Katayama N; Orita M; Yamaguchi T; Furutani M; Hamada N; Takeuchi M; Okada M; Ohta M; Tsukamoto S
Bioorg Med Chem; 2008 Dec; 16(23):10001-12. PubMed ID: 18952447
[TBL] [Abstract][Full Text] [Related]
4. Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase.
Hoover DJ; Lefkowitz-Snow S; Burgess-Henry JL; Martin WH; Armento SJ; Stock IA; McPherson RK; Genereux PE; Gibbs EM; Treadway JL
J Med Chem; 1998 Jul; 41(16):2934-8. PubMed ID: 9685232
[No Abstract] [Full Text] [Related]
5. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes.
Reed MJ; Meszaros K; Entes LJ; Claypool MD; Pinkett JG; Brignetti D; Luo J; Khandwala A; Reaven GM
Diabetologia; 1999 Jan; 42(1):102-6. PubMed ID: 10027587
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
Dang Q; Liu Y; Cashion DK; Kasibhatla SR; Jiang T; Taplin F; Jacintho JD; Li H; Sun Z; Fan Y; DaRe J; Tian F; Li W; Gibson T; Lemus R; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2011 Jan; 54(1):153-65. PubMed ID: 21126019
[TBL] [Abstract][Full Text] [Related]
7. The biomimetic [Cr(3)O(O(2)CCH(2)CH(3))(6)(H(2)O)(3)](+ )decreases plasma insulin, cholesterol, and triglycerides in healthy and type II diabetic rats but not type I diabetic rats.
Sun Y; Clodfelder BJ; Shute AA; Irvin T; Vincent JB
J Biol Inorg Chem; 2002 Sep; 7(7-8):852-62. PubMed ID: 12203022
[TBL] [Abstract][Full Text] [Related]
8. Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
Vu CB; Bemis JE; Disch JS; Ng PY; Nunes JJ; Milne JC; Carney DP; Lynch AV; Smith JJ; Lavu S; Lambert PD; Gagne DJ; Jirousek MR; Schenk S; Olefsky JM; Perni RB
J Med Chem; 2009 Mar; 52(5):1275-83. PubMed ID: 19199480
[TBL] [Abstract][Full Text] [Related]
9. Optimization of brain penetrant 11β-hydroxysteroid dehydrogenase type I inhibitors and in vivo testing in diet-induced obese mice.
Goldberg FW; Dossetter AG; Scott JS; Robb GR; Boyd S; Groombridge SD; Kemmitt PD; Sjögren T; Gutierrez PM; deSchoolmeester J; Swales JG; Turnbull AV; Wild MJ
J Med Chem; 2014 Feb; 57(3):970-86. PubMed ID: 24422550
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities.
Tang H; Yan Y; Feng Z; de Jesus RK; Yang L; Levorse DA; Owens KA; Akiyama TE; Bergeron R; Castriota GA; Doebber TW; Ellsworth KP; Lassman ME; Li C; Wu MS; Zhang BB; Chapman KT; Mills SG; Berger JP; Pasternak A
Bioorg Med Chem Lett; 2010 Oct; 20(20):6088-92. PubMed ID: 20832306
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes.
Crane L; Anastassiadou M; El Hage S; Stigliani JL; Baziard-Mouysset G; Payard M; Leger JM; Bizot-Espiard JG; Ktorza A; Caignard DH; Renard P
Bioorg Med Chem; 2006 Nov; 14(22):7419-33. PubMed ID: 16889967
[TBL] [Abstract][Full Text] [Related]
12. Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model.
Novelli M; D'Aleo V; Lupi R; Paolini M; Soleti A; Marchetti P; Masiello P
Pancreas; 2007 Nov; 35(4):e10-7. PubMed ID: 18090226
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats.
Wang Y; Campbell T; Perry B; Beaurepaire C; Qin L
Metabolism; 2011 Feb; 60(2):298-305. PubMed ID: 20304443
[TBL] [Abstract][Full Text] [Related]
14. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
[TBL] [Abstract][Full Text] [Related]
15. Antidiabetic effect of Symplocos cochinchinensis (Lour.) S. Moore. in type 2 diabetic rats.
Sunil C; Ignacimuthu S; Agastian P
J Ethnopharmacol; 2011 Mar; 134(2):298-304. PubMed ID: 21182925
[TBL] [Abstract][Full Text] [Related]
16. (WO2011057959) indole and indazole derivatives as glycogen synthase activators: a patent evaluation.
Skaltsounis AL; Gaboriaud-Kolar N
Expert Opin Ther Pat; 2011 Dec; 21(12):1925-9. PubMed ID: 21988345
[TBL] [Abstract][Full Text] [Related]
17. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER
Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804
[TBL] [Abstract][Full Text] [Related]
18. Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents.
Aicher TD; Balkan B; Bell PA; Brand LJ; Cheon SH; Deems RO; Fell JB; Fillers WS; Fraser JD; Gao J; Knorr DC; Kahle GG; Leone CL; Nadelson J; Simpson R; Smith HC
J Med Chem; 1998 Nov; 41(23):4556-66. PubMed ID: 9804695
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
[TBL] [Abstract][Full Text] [Related]
20. Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.
Sinz C; Bittner A; Brady E; Candelore M; Dallas-Yang Q; Ding V; Jiang G; Lin Z; Qureshi S; Salituro G; Saperstein R; Shang J; Szalkowski D; Tota L; Vincent S; Wright M; Xu S; Yang X; Zhang B; Tata J; Kim R; Parmee ER
Bioorg Med Chem Lett; 2011 Dec; 21(23):7124-30. PubMed ID: 22030028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
